These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 38378887)

  • 21. Clinical characteristics of late-onset neuromyelitis optica spectrum disorder: A multicenter retrospective study in Korea.
    Seok JM; Cho HJ; Ahn SW; Cho EB; Park MS; Joo IS; Shin HY; Kim SY; Kim BJ; Kim JK; Cho JY; Huh SY; Kwon O; Lee KH; Kim BJ; Min JH
    Mult Scler; 2017 Nov; 23(13):1748-1756. PubMed ID: 28058965
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Neuromyelitis Optica Spectrum Disorder With Anti-Aquaporin-4 Antibody: Outcome Prediction Models.
    Wang L; Du L; Li Q; Li F; Wang B; Zhao Y; Meng Q; Li W; Pan J; Xia J; Wu S; Yang J; Li H; Ma J; ZhangBao J; Huang W; Chang X; Tan H; Yu J; Zhou L; Lu C; Wang M; Dong Q; Lu J; Zhao C; Quan C
    Front Immunol; 2022; 13():873576. PubMed ID: 35432315
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Widespread cortical thinning in patients with neuromyelitis optica spectrum disorder.
    Kim SH; Kwak K; Hyun JW; Jeong IH; Jo HJ; Joung A; Kim JH; Lee SH; Yun S; Joo J; Lee JM; Kim HJ
    Eur J Neurol; 2016 Jul; 23(7):1165-73. PubMed ID: 27108769
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Eye movement abnormalities in AQP4-IgG positive neuromyelitis optica spectrum disorder.
    Sun H; Cui S; Gao F; You Q; Li Y; Wang J; Zhang X
    J Neurol Sci; 2018 Jan; 384():91-95. PubMed ID: 29249386
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Risk factors associated with permanent disability in neuromyelitis optica spectrum disorders.
    Valdivia-Tangarife ER; Gamez-Nava JI; Cortés-Enríquez F; Mireles-Ramírez MA; Gonzalez-López L; Saldaña-Cruz AM; Macías-Islas MA
    Mult Scler Relat Disord; 2022 Dec; 68():104114. PubMed ID: 36037753
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy of azathioprine, mycophenolate mofetil, and rituximab in the treatment of neuromyelitis optica spectrum disorder and analysis of prognostic factors.
    Zhang L; Tian J; Dong X; Jia Z; Sun Y; Guo L; Tan G; Li B
    Neurol Sci; 2022 Apr; 43(4):2651-2658. PubMed ID: 34585292
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Correlations among disability, anti-AQP4 antibody status and prognosis in the spinal cord involved patients with NMOSD.
    Hsu JL; Liao MF; Chang KH; Cheng MY; Ro LS
    BMC Neurol; 2021 Apr; 21(1):153. PubMed ID: 33836682
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Structural and functional hippocampal alterations in Multiple sclerosis and neuromyelitis optica spectrum disorder.
    Zheng F; Li Y; Zhuo Z; Duan Y; Cao G; Tian D; Zhang X; Li K; Zhou F; Huang M; Li H; Li Y; Zeng C; Zhang N; Sun J; Yu C; Han X; Hallar S; Barkhof F; Liu Y
    Mult Scler; 2022 Apr; 28(5):707-717. PubMed ID: 34379008
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Anti-thyroid antibodies and thyroid function in neuromyelitis optica spectrum disorders.
    Wang X; Yi H; Liu J; Li M; Mao ZF; Xu L; Peng FH
    J Neurol Sci; 2016 Jul; 366():3-7. PubMed ID: 27288767
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cross-modal plasticity among sensory networks in neuromyelitis optica spectrum disorders.
    Rocca MA; Savoldi F; Valsasina P; Radaelli M; Preziosa P; Comi G; Falini A; Filippi M
    Mult Scler; 2019 Jun; 25(7):968-979. PubMed ID: 29771186
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Structural covariance in subcortical regions in multiple sclerosis and neuromyelitis optica spectrum disorders: An MRI-based study with automated brain volumetry.
    Xie Y; Zhang Y; Yao Y; Liu D; Zhu H; Liu C; Zhu W
    Mult Scler Relat Disord; 2023 Feb; 70():104516. PubMed ID: 36669244
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Expression and Clinical Correlation Analysis Between Repulsive Guidance Molecule a and Neuromyelitis Optica Spectrum Disorders.
    Tang J; Zeng X; Yang J; Zhang L; Li H; Chen R; Tang S; Luo Y; Qin X; Feng J
    Front Immunol; 2022; 13():766099. PubMed ID: 35185873
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Association of Visual Impairment in Neuromyelitis Optica Spectrum Disorder With Visual Network Reorganization.
    Finke C; Zimmermann H; Pache F; Oertel FC; Chavarro VS; Kramarenko Y; Bellmann-Strobl J; Ruprecht K; Brandt AU; Paul F
    JAMA Neurol; 2018 Mar; 75(3):296-303. PubMed ID: 29297041
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The mediating effect of health-related hardiness on the degree of physical disability and perceived stress in Chinese female patients with neuromyelitis optica spectrum disorder.
    Xu Y; Su X; Lu X; Zhang M; Wang W; Ding D; Chao Q; Jiang H
    Mult Scler Relat Disord; 2019 Oct; 35():67-72. PubMed ID: 31351263
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Personalized estimates of morphometric similarity in multiple sclerosis and neuromyelitis optica spectrum disorders.
    Sun J; Zhao W; Xie Y; Zhou F; Wu L; Li Y; Li H; Li Y; Zeng C; Han X; Liu Y; Zhang N
    Neuroimage Clin; 2023; 39():103454. PubMed ID: 37343344
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Brain magnetic resonance imaging features in multiple sclerosis and neuromyelitis optica spectrum disorders patients with or without aquaporin-4 antibody in a Latin American population.
    Silveira F; Pappolla A; Sánchez F; Marques VD; de Castillo IS; Tkachuk V; Caride A; Castillo MC; Cristiano E; Cruz CA; Diégues Serva GB; Dos Santos AC; Moreira CL; López PA; Patrucco L; Molina O; Pettinicchi JP; Carnero Contentti E; Rojas JI
    Mult Scler Relat Disord; 2020 Jul; 42():102049. PubMed ID: 32251869
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Asian and African/Caribbean AQP4-NMOSD patient outcomes according to self-identified race and place of residence.
    Soares-Dos-Reis R; Tsz-Ching JL; Kim SH; Jacob A; Whittam D; Berthelot E; Paul F; Nakashima I; Tye JSN; De Seze J; Jitprapaikulsan J; Tan K; Yang L; Elsone L; Leite MI; Mealy MA; Levy M; Fan M; Siebert N; Asgari N; Cabre P; Siritho S; Pittock SJ; Wing-Ho SC; Senger T; Yeo T; Takai Y; Pandit L; Kim HJ; Palace J
    Mult Scler Relat Disord; 2021 Aug; 53():103080. PubMed ID: 34171683
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of immunotherapies and prognostic predictors in neuromyelitis optica spectrum disorder: a prospective cohort study.
    Shi Z; Du Q; Chen H; Zhang Y; Qiu Y; Zhao Z; Wang J; Yan C; Zhang Q; Yang M; Zhou H
    J Neurol; 2020 Apr; 267(4):913-924. PubMed ID: 31776721
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Health-related quality of life in neuromyelitis optica spectrum disorder patients in an Argentinean cohort.
    Carnero Contentti E; Eizaguirre MB; López PA; Rojas JI; Tkachuk V; Alonso R
    Mult Scler Relat Disord; 2022 Mar; 59():103647. PubMed ID: 35124305
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Factors influencing the degree of disability in patients with neuromyelitis optica spectrum disorders.
    Shi L; Li D; Zhang Y; Wang J; Fu J; Liu X; Wang P
    Eur J Med Res; 2023 Oct; 28(1):426. PubMed ID: 37821922
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.